Cleave Biosciences, Inc.: Series A $44M

Posted in I - Series A, Q - 4Q11, R - WEST, X - Oncology, XX - CA

Cleave Biosciences (Burlingame, CA) a preclinical-stage pharmaceutical company focused on small molecules for oncology, closed a $42M Series A financing. Participants include US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management.

Jan

2012

Pulmatrix, Inc.: Series B $14M

Posted in I - Series B, Q - 3Q11, R - NORTH EAST, X - Asthma, X - COPD, XX - MA

Pulmatirx (Lexington, MA) a clinical-stage biotech company focused on COPD and astham, closed a $14M Series B financing. Participants include Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund. Thanx for your patience as we catch-up.

Jan

2011

Pearl Therapeutics, Inc.: Series C $69M

Posted in I - Series C, Q - 4Q10, R - WEST, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage small molecule company focused on combination therapy for chronic obstructive pulmonary disease, closed a $69M Series C financing. Participants include Vatera Healthcare Partners, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Sep

2010

Relypsa, Inc.: Series B $70M

Posted in I - Series B, Q - 3Q10, R - WEST, X - Cardiology, X - Hyperkalemia, XX - CA

Relypsa (Santa Clara, CA) a clinical-stage developer of a therapeutic for hyperkalemia in congestive heart failure patients, closed a $70M Series B financing. Participants include 5AM Ventures, New Leaf Partners, Delphi Ventures and OrbiMed Advisors.

Jun

2010

Incline Therapeutics, Inc.: Series A $43M

Posted in I - Series A, Q - 2Q10, R - WEST, X - Drug:Device Combo, X - Pain, XX - CA

Incline Therapeutics (Redwood City, WA) a clinical-stage drug:device combo company focused on pain, closed a $43M Series A financing. Participants include Frazier Healthcare Ventures, 5AM Ventures, Technology Partners, Adams Street Partners, Saints Capital Partners and Emergent Medical Partners.

Jun

2010

Igenica, Inc.: Series B $24M

Posted in I - Series B, Q - 2Q10, R - WEST, X - Antibody, X - Oncology, X - Therapeutic Platform, XX - CA

Igencia (Burlingame, CA) a development-stage biopharmaceutical company focused on the discovery of tumor antigens and in vivo antibody screen platforms for various oncologic indications, closed a $24M Series B financing. Participants include The Column Group, OrbiMed and 5AM Ventures.

Mar

2010

Pearl Therapeutics, Inc.: Series B $15M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Asthma, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Feb

2010

Flexion Therapeutics, Inc.: Series A $9M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Autoimmune, X - IBD, X - Tinnitus, XX - MA

Flexion Therapeutics (Woburn, MA) a clinical-stage biopharma focused on autoimmune disease, ulcerative colitis and tinnitus, closed a $9M Series A financing, bringing the total round to $42M. Participants include Pfizer Venture Investments, Versant Ventures, 5AM Ventures and Sofinnova Ventures.

Jan

2010

Pulmatrix, Inc.: Series B $30.2M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - Respiratory, X - RSV, XX - MA

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Jan

2010

Flexion Therapeutics, Inc.: Series A $33M

Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Specialty Pharma, XX - MA

Flexion Therapeutics (Woburn, MA) advances high value specialty drug candidates through clinically meaningful proof of concept and beyond, the company plans to announce deals with three major pharmas shortly, closed a $33M Series A financing. Participants include Versant Ventures, 5AM Ventures and Sofinnova Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...